On February 25, Nektar Therapeutics (NASDAQ:NKTR) announced the enrollment of the first patient in SUMMIT-07, its initial Phase 3 study of NKTR-181, a first-in-class, opioid analgesic molecule with a slow rate of entry into the brain. This slow rate of entry is designed to reduce the euphoria that can lead to the abuse of current opioid analgesics.1 SUMMIT-07 will evaluate the efficacy, safety and tolerability of NKTR-181 in patients with chronic low back pain who are also opioid-naïve (new to treatment). On Friday shares of Nektar Therapeutics (NASDAQ:NKTR) closed at $13.02. Company’s sales growth for last 5 years was 22.80% and EPS growth for next 5 years is recorded as 42.50%.
JPMorgan Chase & Co. (NYSE:JPM) announced that it has released the results of its “company-run” 2015 Dodd-Frank Act Stress Test for JPMorgan Chase & Co. and certain select subsidiaries that are subject to the DFAST rules. JPMorgan Chase & Co. (NYSE:JPM) in last trading activity decreased -1.79% to close at $60.89. Company weekly performance is -0.64% while its quarterly performance stands at -0.43%. JPMorgan Chase & Co. (NYSE:JPM) is -3.48% away from its 52 week high.
Zacks reissued their neutral rating on shares of DaVitaHealthCare Partners (NYSE:DVA) in a research report released on Wednesday morning. Zacks currently has a $80.00 price objective on the stock. On last trading day DaVita HealthCare Partners Inc. (NYSE:DVA) moved up 0.91% to close at $77.63. Its volatility for the week is 1.75% while volatility for the month is 1.70%. DVA’s sales growth for past 5 years was 16.00% and its EPS growth for past 5 years was 10.40%. DaVita HealthCare Partners Inc. (NYSE:DVA) monthly performance is 2.20%.
Marrone Bio Innovations, Inc. (NASDAQ:MBII) announced that it will be presenting at the 27th Annual ROTH Conference on Monday, March 9, 2015 at 5:30 p.m. PT in Dana Point, California. Marrone Bio Innovations, Inc. (NASDAQ:MBII) has 3.00% insider ownership while its institutional ownership stands at 56.90%. In last trading activity company’s stock closed at $3.58.
On March 3, it was reported that, Pfizer Inc. (NYSE:PFE)’s blockbuster vaccine against pneumonia and other bacterial infections has won another approval, for use in European Union residents aged 18 and older. Prevnar 13, called Prevenar 13 in some countries, is the best-selling vaccine ever. On Friday shares of Pfizer Inc. (NYSE:PFE) closed at $33.97. Company’s sales growth for last 5 years was 0.10% and EPS growth for next 5 years is recorded as 2.17%.